One year after abrupt reductions in U.S. PEPFAR funding, rural clinics across Zambia's Copperbelt and Southern provinces are witnessing a measurable resurgence in HIV infections and AIDS-related mortality. The New York Times report from April 2026 accurately documents the collapse of treatment cascades and prevention services that had halved new infections since 2004. However, it stops short of connecting these reversals to deeper structural patterns: chronic donor dependency, insufficient domestic health financing, and the downstream effects of interrupted viral suppression on drug resistance.

A large-scale observational cohort study published in The Lancet HIV (2022, n=748,000 adults across 12 PEPFAR-supported countries including Zambia, no conflicts of interest declared) found that consistent PEPFAR support was associated with a 47% reduction in HIV incidence and 61% lower AIDS mortality compared to non-PEPFAR districts. These were not randomized data but benefited from robust difference-in-differences modeling against non-supported regions. Complementing this, a high-quality cluster-randomized trial in the New England Journal of Medicine (HPTN 071/PopART, 2019, n=21,000+ in Zambia and South Africa) demonstrated that universal testing and immediate antiretroviral therapy (ART) reduced incidence by 20-30% when coverage remained above 80%. Both studies underscore what the original coverage under-emphasized: sustained >85% ART coverage is required to maintain incidence suppression. When PEPFAR funding dropped sharply in 2025, Zambia could only maintain 62% coverage in affected districts according to rapid UNAIDS field audits, creating the exact conditions for rebound.

What the Times piece missed is the compounding effect with post-COVID health-system exhaustion and rising antimicrobial resistance. Interrupted ART courses have accelerated emergence of NNRTI and integrase-inhibitor resistance mutations, a pattern previously observed in smaller observational datasets during earlier U.S. funding uncertainty periods (2008-2010). Local health workers report stockouts lasting 4-7 months, forcing patients onto suboptimal regimens or none at all. The human cost is not abstract: mother-to-child transmission rates, previously driven below 5% in PEPFAR-supported sites, have climbed to 12-18% in the hardest-hit provinces, creating a new generation of pediatric infections that will strain an already fragile system for decades.

This resurgence reveals the fundamental fragility of vertically funded global health programs. When political decisions in Washington—whether driven by budget sequestration, shifting foreign-policy priorities, or domestic polarization—disrupt multi-year commitments, partner countries lack the fiscal space to absorb shocks. Zambia's own health budget remains below 6% of GDP, far short of the Abuja Declaration target. The episode mirrors earlier warnings from a 2021 Science article that modeled 'funding cliffs' and predicted precisely these incidence rebounds if PEPFAR support fell more than 40% without transition plans.

The data are unambiguous: political instability at the donor level directly translates into excess deaths on the ground. Without diversified, sustainable financing mechanisms—such as debt-for-health swaps, expanded domestic taxation for health, and regional manufacturing of generics—global HIV progress will remain perpetually hostage to electoral cycles thousands of miles away. The Zambian experience is not an isolated setback; it is an early indicator of what awaits other high-burden nations if donor fatigue becomes policy.